Boston Scientific Corporation vs UiPath Inc — how do they compare? Boston Scientific Corporation trades at $42.65 (market cap $66.37B), while UiPath Inc trades at $12.02 (market cap $6.14B). The key difference: Boston Scientific Corporation is far larger — about 10.8× UiPath Inc's market cap, and UiPath Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | PATH | |
|---|---|---|
Market Cap | $66.37B | $6.14B |
Sector | Health | Technology |
52-Week High | $108.14 | $19.29 |
52-Week Low | $42.63 | $9.38 |
Enterprise Value | $75.94B | $4.92B |
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →